A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 19, 2025

Primary Completion Date

April 14, 2028

Study Completion Date

May 19, 2028

Conditions

Cytomegalovirus Prophylaxis

Interventions

DRUG

Letermovir

Administered orally (as tablets/pellets) or via gastrostomy or nasogastric tube (as pellets) for 7 consecutive days.

Trial Locations (1)

RECRUITING

Lucile Packard Children's Hospital (0001), Palo Alto

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY